目的：研究宫颈DNA倍体测定联合HPV分型对宫颈癌筛查的临床意义。方法将2013年7月至2016年7月我院收治的宫颈癌患者78例按随机数字表法分为各39例的观察组与对照组。观察组采用宫颈DNA倍体与 HPV分型综合测定的方法，对照组采用传统的宫颈液基细胞学联合HPV检测，比较两组检测准确率。结果观察组发现阳性患者37例，筛查正确率为94.87%，对照组则仅发现阳性患者34例，筛查正确率为87.18%；观察组检测出的原位癌占阳性的比例为56.76%；对照组检测出的原位癌占阳性的比例为50.00%，组间差异均具有统计学意义（ P<0.05）。结论宫颈 DNA倍体测定联合 HPV分型筛查宫颈癌准确性高，在临床上具有较高的应用价值。%Objective To investigate the clinical meaning of cervical DNA ploidy determination combined with HPV typing for cervical cancer screening. Methods Seventy-eight cases of patients with cervical cancer admitted in our hospital from July 2013 to July 2016 were randomly divided into observation group and control group, with 39 cases in each group. The observation group accepted cervical DNA ploidy determination combined with HPV typing, while the control group received traditional cervical liquid-based cytology combined with HPV detection. The correct rate of screening was compared between the two groups. Results The correct rate of screening was 94.87% (37 cases) in the observation group, which was significantly higher than 87.18%(34 cases) in the control group (P<0.05). The proportion of carcinoma in situ in the observation group was 56.76%, and the control group was 50.00%, the difference was statistically significant (P<0.05). Conclusion Cervical DNA ploidy determination combined with HPV typing for cervical cancer screening has an advantage of high accuracy, with high application value in clinic.
展开▼
